Novartis Q3 guidance raise signals improving execution, but quality of beat still needs scrutiny

What happened

Novartis raised full-year 2026 core operating income guidance after reporting 4% sales growth, a notable improvement from first-half constant-currency decline of 2% and prior guidance for low-single-digit core income decline. The upgrade likely reflects better-than-expected third-quarter performance, driven by continued strength in priority brands and possibly early contribution from newly approved products like Pluvicto mHSPC, while Entresto generic erosion remains a drag. Rhapsido peak sales guidance raised to over $4 billion across combined indications, signaling management confidence in newly launched dermatology/immunology assets. However, the raise should be viewed skeptically because first-half 2026 operating margin had fallen to 32.6% and free cash flow declined 12%, and guidance increases can reflect one-off items or favorable timing rather than durable operating leverage. Investors must still monitor whether group sales growth translates into sustainable margin recovery and whether late-stage pipeline catalysts materialize as promised.

Implication

The positive sales growth and raised guidance suggest the commercial offset engine is finally gaining traction at the enterprise level, but the quality of the raise matters more than the headline. Investors should await confirmation that the improved outlook is driven by volume growth in Kisqali, Kesimpta, Pluvicto, and Scemblix rather than one-time items or currency effects. The Rhapsido peak sales increase to over $4 billion provides an additional growth stream, yet its contribution to near-term earnings may be modest given launch spending. Given the stock currently trades near $152, above the attractive entry of $140 but still below the $170 trim level, the risk/reward has improved but remains balanced; we maintain a wait-and-see stance for more evidence of margin stabilization and successful pipeline readouts. A sustained re-rating would require Q4 2026 results to show clean group-level growth and at least one major late-stage success from pelacarsen, remibrutinib, or del-desiran.

Thesis delta

The thesis shifts from a cautious wait based on first-half group sales decline and margin compression to a more balanced view following third-quarter sales growth and an upward revision to core operating income guidance. However, the shift is not yet decisive because first-half free cash flow declined and the premium valuation still depends on second-half pipeline readouts and Pluvicto approval. We upgrade our near-term conviction modestly but retain the WAIT rating until there is clearer evidence that the improved sales trend is sustainable and margins are recovering.